Journal · 8309333
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2 sourcesjournal-index-2026-11-06-0.2.0
Download JSON
Cite this record
ConductScience Library. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Journal index, record 8309333. Release journal-index-2026-11-06-0.2.0, 6 Nov 2026. https://conductscience.org/library/journal-index/8309333
On this page
Journal
Counted by ScienceGraph from its copy of PubMed, by the NLM ID each paper's record states: papers from 1959 on, and no preprints, since until the copy is rebuilt from NLM's own files it holds few of PubMed's papers from before 1959 and about half its preprints.
- Title
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- NLM Catalog
Years44
Each paper counts in the year of its issue, as its record states. PubMed's search for a year also finds papers that appeared online that year, so its count can be higher. A part year is our copy's own year or later.
| Year | Papers | With a copy in PMC | Retracted | With NIH grants | With a ClinicalTrials.gov number | Source |
|---|---|---|---|---|---|---|
| 2026, part year | 594 | 150 | 0 | 77 | 128 | PubMed |
| 2025 | 569 | 249 | 0 | 152 | 171 | PubMed |
| 2024 | 599 | 280 | 0 | 198 | 179 | PubMed |
| 2023 | 803 | 339 | 0 | 246 | 200 | PubMed |
| 2022 | 584 | 245 | 0 | 176 | 134 | PubMed |
| 2021 | 552 | 248 | 0 | 164 | 141 | PubMed |
| 2020 | 592 | 297 | 0 | 218 | 138 | PubMed |
| 2019 | 563 | 264 | 1 | 179 | 112 | PubMed |
| 2018 | 645 | 235 | 1 | 188 | 134 | PubMed |
| 2017 | 764 | 256 | 0 | 224 | 16 | PubMed |
1 to 10 of 44
See all 44 yearsPublication types61
NLM's publication types, as each record states them. A paper can have several.
| Type | Papers | Source |
|---|---|---|
| Journal Article | 21,253 | PubMed |
| Research Support, Non-U.S. Gov't | 10,779 | PubMed |
| Comment | 5,933 | PubMed |
| Letter | 4,373 | PubMed |
| Randomized Controlled Trial | 4,224 | PubMed |
| Multicenter Study | 4,056 | PubMed |
| Clinical Trial | 4,022 | PubMed |
| Research Support, N.I.H., Extramural | 3,623 | PubMed |
| Research Support, U.S. Gov't, P.H.S. | 2,910 | PubMed |
| Comparative Study | 2,532 | PubMed |
1 to 10 of 61
See all 61 publication typesRetracted papers14
Papers whose PubMed record is typed Retracted Publication, with the notice PubMed links.
| PMID | Title | Year | Retraction notice | Source |
|---|---|---|---|---|
| 30721110 | TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | 2019 | 33999659 | PubMed |
| 29244528 | Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. | 2018 | 32822279 | PubMed |
| 26786924 | Inferring the Effects of Cancer Treatment: Divergent Results From Early Breast Cancer Trialists' Collaborative Group Meta-Analyses of Randomized Trials and Observational Data From SEER Registries. | 2016 | 27528722 | PubMed |
| 25311221 | Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. | 2016 | 37566792 | PubMed |
| 21482993 | Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. | 2011 | 22204025 | PubMed |
| 20837949 | Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. | 2010 | 22029053 | PubMed |
| 19380445 | Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. | 2009 | 23304713 | PubMed |
| 17906199 | Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. | 2007 | 21148129 | PubMed |
| 17290060 | An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. | 2007 | 22451975 | PubMed |
| 16110016 | Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. | 2005 | 16829659 | PubMed |
1 to 10 of 14
See all 14 retracted papersNewest papers20
The twenty newest papers in our copy of PubMed, by year and then PMID.
| PMID | Title | Year | Source |
|---|---|---|---|
| 42987248 | Perfluoroalkyl Substances and Estrogen Receptor‑Negative Breast Cancer: Looking Beyond Traditional Risk Factors. | 2026 | PubMed |
| 42987247 | Per- and Polyfluoroalkyl Substance Exposure and Breast Cancer Incidence in the Sister Study. | 2026 | PubMed |
| 42981561 | International Initiative on a Refined Staging System for Medullary Thyroid Cancer: A Multinational Multicenter Study. | 2026 | PubMed |
| 42981545 | Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations. | 2026 | PubMed |
| 42976310 | When Practice Outpaces Evidence: Comparative Evidence for Stereotactic Ablative Radiotherapy Versus Surgical Resection for Stage I Non‑Small Cell Lung Cancer. | 2026 | PubMed |
| 42976306 | Feasibility and Tolerability of Chemoimmunotherapy Given During Induction for Treatment of Patients With High-Risk Neuroblastoma: A Report From the Children's Oncology Group. | 2026 | PubMed |
| 42970669 | Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non-Small Cell Lung Cancer: An Emulated Target Trial. | 2026 | PubMed |
| 42970668 | Immunochemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer: A Randomized Controlled Trial. | 2026 | PubMed |
| 42962160 | From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. | 2026 | PubMed |
| 42962158 | Methylphenidate for Hematologic Cancer-Related Fatigue: A Randomized Clinical Trial. | 2026 | PubMed |
| 42962156 | Erratum: Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. | 2026 | PubMed |
| 42956324 | Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4. | 2026 | PubMed |
| 42950186 | Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study. | 2026 | PubMed |
| 42950185 | Immunotherapy With Stereotactic Body Radiation Therapy in Early-Stage Non‑Small Cell Lung Cancer: Matching Risk, Biology, and Timing. | 2026 | PubMed |
| 42950173 | KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer. | 2026 | PubMed |
| 42945508 | PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0. | 2026 | PubMed |
| 42945507 | Art as a Shared Space: Tracing the Unseen Through a Body Map. | 2026 | PubMed |
| 42945506 | Advancing Cascade Genetic Testing for BRCA1/2 Pathogenic Variants Beyond the Academic Research Setting. | 2026 | PubMed |
| 42945503 | Was Futility in RADICAL Robust to Analytic Specification? | 2026 | PubMed |
| 42945497 | Reply to: Was Futility in RADICAL Robust to Analytic Specification? | 2026 | PubMed |
Data dates
The date of each source this release read.
- Our copy of PubMed
- 2026-11-06
- NLM's journal list
- 2026-11-01
Sources 2
- NLM's journal listNLM's terms
- PubMedNLM's terms
Each source's terms
- NLM's journal listNLM's
- PubMedNLM's terms
For software
Read this journal from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/journal-index/v1/8309333
GET https://conductscience.org/api/journal-index/v1/8309333/years?page=2